🏢 官网IRRGNXCodex · 实盘不做把握 9/10
北京时间·🕒 发布 08-03 19:05:00(美东 07:05)·⟳ 抓取 08-03 19:05:22·⚡ 决策 08-04 13:00:40 +17h55m·84.5 天前
REGENXBIO宣布将召开二季度业绩电话会
本次只是公司例行预告8月6日召开二季度财报电话会，未披露业绩数据、指引变化、临床进展或交易性新增事实。
📄 原文RGNX↗ 原文
ROCKVILLE, Md. , Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a confere…
不做 REGENXBIO（RGNX.US）
例行财报电话会预告，没有披露二季度业绩、指引、临床或商业化新增事实，方向和edge都无法形成，当前不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 low · price-in 风险 high ↗
关键理由
- 本次只是公司例行预告8月6日召开二季度财报电话会，未披露业绩数据、指引变化、临床进展或交易性新增事实。
主要风险
- 真正可能影响股价的是8月6日实际财报和经营更新，而不是本次会议通知本身。
原文全文
展开原文 · 1,977 字
ROCKVILLE, Md.
,
Aug. 3, 2026
/PRNewswire/ --
REGENXBIO Inc.
(Nasdaq: RGNX) today announced that it will host a conference call on
Thursday, August 6
, at
8:00 a.m. ET
to discuss its financial results for the second quarter ended
June 30, 2026
, and operational highlights.
Listeners can register for the webcast via this
link
. Analysts wishing to participate in the question and answer session should use this
link
. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT
REGENXBIO Inc.
REGENXBIO
is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009,
REGENXBIO
has pioneered the field of AAV gene therapy.
REGENXBIO
is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with
REGENXBIO's
AAV platform, including those receiving Novartis' ZOLGENSMA®.
REGENXBIO's
investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit
www.REGENXBIO.com
.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-august-6-to-discuss-second-quarter-2026-financial-results-and-operational-highlights-302840354.html
SOURCE
REGENXBIO Inc.
,
Aug. 3, 2026
/PRNewswire/ --
REGENXBIO Inc.
(Nasdaq: RGNX) today announced that it will host a conference call on
Thursday, August 6
, at
8:00 a.m. ET
to discuss its financial results for the second quarter ended
June 30, 2026
, and operational highlights.
Listeners can register for the webcast via this
link
. Analysts wishing to participate in the question and answer session should use this
link
. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT
REGENXBIO Inc.
REGENXBIO
is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009,
REGENXBIO
has pioneered the field of AAV gene therapy.
REGENXBIO
is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with
REGENXBIO's
AAV platform, including those receiving Novartis' ZOLGENSMA®.
REGENXBIO's
investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit
www.REGENXBIO.com
.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:
https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-august-6-to-discuss-second-quarter-2026-financial-results-and-operational-highlights-302840354.html
SOURCE
REGENXBIO Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。